The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Jan 27, 2025
auto_awesome
Jim Doherty, President and Chief Development Officer at Acumen Pharmaceuticals, shares his extensive experience in developing therapies for CNS diseases. He discusses the historical challenges of Alzheimer’s treatment, the controversies over new amyloid-targeting drugs, and the pivotal role of biomarkers in personalized medicine. Highlighting Acumen's promising candidate, Sobernatug, he reveals its innovative approach to targeting soluble A-beta oligomers, while emphasizing the importance of collaboration and evolving strategies in CNS drug development.
Dr. Jim Doherty highlights the critical advancements in Alzheimer's therapeutics, emphasizing the significance of recent drug approvals after a prolonged stagnation in the field.
Acumen Pharmaceuticals seeks to innovate in CNS treatments by using Sobernatug to target soluble amyloid oligomers, aiming for improved patient outcomes and administration methods.
Deep dives
Dr. Jim Doherty's Commitment to Neuroscience
Dr. Jim Doherty has dedicated his career to developing new therapeutics for various brain disorders, driven by the significant unmet need in the central nervous system (CNS) field. He emphasizes the vast range of conditions that require innovative treatments, including neurodegenerative diseases like Alzheimer's, seizure disorders, and psychiatric conditions such as major depression. His longstanding interest in brain health stems from the complex challenges these disorders present, as well as the potential to positively impact the lives of patients. Throughout his career, the advancements in therapeutic modalities, such as large molecules and genetic therapies, have fueled his motivation to continue working in neuroscience.
The Evolution of Alzheimer's Therapeutics
The podcast discusses the historical challenges faced in developing treatments for Alzheimer's disease, highlighting a long period of stagnation before recent therapeutic approvals for amyloid-targeting drugs. Dr. Doherty reflects on the perseverance of investigators who have dedicated significant time to treat this disorder, despite repeated failures in clinical trials. He acknowledges that while symptomatic treatments have seen limited success, the recent approvals represent a breakthrough in modifying disease progression. The dialogue underscores the importance of this persistence, as the field now stands at a pivotal moment for further advancements in Alzheimer’s therapeutics.
Acumen Pharmaceuticals' Unique Approach
Acumen Pharmaceuticals, under Dr. Doherty's leadership, aims to differentiate itself in the Alzheimer's market with its monoclonal antibody, Sobernatug, which targets soluble amyloid oligomers rather than larger plaques. This approach is based on evidence that these smaller oligomers have a direct correlation with cognitive impairment and synaptic damage. The company is also exploring avenues for subcutaneous administration to increase patient accessibility and comfort, addressing some of the practical challenges associated with intravenous therapies. By prioritizing both efficacy and safety, Acumen's strategy aims to provide a meaningful impact on Alzheimer’s treatment outcomes.
Navigating Clinical Trials and Funding Challenges
Dr. Doherty shares insights on the financial considerations crucial for navigating the expensive landscape of clinical trials, especially during the challenging times biotech faces. He emphasizes the importance of careful capital management and strategic prioritization to ensure sufficient resources throughout the sequential nature of drug development. In the context of the CNS market, he notes the potential for renewed investor interest as recent therapeutic successes give hope for addressing formidable unmet medical needs. The ongoing development of biomarkers is key, offering a pathway to better match treatments with appropriate patient populations for improved clinical outcomes.
Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape.We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.